Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SJS
MCID: SVR097
MIFTS: 72

Severe Cutaneous Adverse Reaction (SJS)

Categories: Genetic diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Severe Cutaneous Adverse Reaction

About this section

MalaCards integrated aliases for Severe Cutaneous Adverse Reaction:

Name: Severe Cutaneous Adverse Reaction 57 38
Stevens-Johnson Syndrome 57 38 12 59 75 55 6 44 15 73
Toxic Epidermal Necrolysis 57 59 75 55 6 73
Susceptibility to Severe Cutaneous Adverse Reaction 29 6 40
Hypersensitivity Syndrome, Carbamazepine-Induced, Susceptibility to 57 13
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum 73
Stevens-Johnson Syndrome/toxic Epidermal Necrolysis Spectrum 59
Severe Cutaneous Adverse Reaction, Susceptibility to 57
Hypersensitivity Syndrome, Carbamazepine-Induced 57
Toxic Epidermal Necrolysis, Susceptibility to 57
Stevens-Johnson Syndrome, Susceptibility to 57
Dermatostomatitis, Stevens Johnson Type 59
Dermatostomatitis Stevens Johnson Type 75
Drug-Induced Stevens Johnson Syndrome 73
Stevensjohnson Syndrome 76
Toxic Epidermolysis 59
Lyell Syndrome 59
Sjs-Ten 59
Sjs 75
Ten 75

Characteristics:

Orphanet epidemiological data:

59
toxic epidermal necrolysis
Inheritance: Not applicable; Age of onset: All ages;
stevens-johnson syndrome
Inheritance: Not applicable; Age of onset: All ages;
stevens-johnson syndrome/toxic epidermal necrolysis spectrum
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare skin diseases


Sources

Summaries for Severe Cutaneous Adverse Reaction

About this section
UniProtKB/Swiss-Prot : 75 Stevens-Johnson syndrome: A rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.

MalaCards based summary : Severe Cutaneous Adverse Reaction, also known as stevens-johnson syndrome, is related to stevens-johnson syndrome/toxic epidermal necrolysis and paraneoplastic pemphigus. An important gene associated with Severe Cutaneous Adverse Reaction is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Allograft rejection. The drugs Lamivudine and Nevirapine have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are sudden cardiac death and dysphagia

Disease Ontology : 12 A skin disease that is characterized by ulceration of less than 10 percent of the surface area of the body. The disease is often precipitated by the use of medications, such as antibiotics or antiepileptics, or onset of infection.

Wikipedia : 76 Stevens�??Johnson syndrome (SJS) is a type of severe skin reaction. Together with toxic epidermal... more...

Description from OMIM: 608579
Sources

Related Diseases for Severe Cutaneous Adverse Reaction

About this section

Diseases related to Severe Cutaneous Adverse Reaction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 286)
# Related Disease Score Top Affiliating Genes
1 stevens-johnson syndrome/toxic epidermal necrolysis 31.9 EPHX1 FAS HLA-A HLA-B HLA-C IKZF1
2 paraneoplastic pemphigus 30.6 HLA-A HLA-B HLA-C
3 herpes zoster 30.4 HCP5 HLA-A HLA-B
4 acute graft versus host disease 30.3 FASLG GZMB TNF
5 hematopoietic stem cell transplantation 30.3 HLA-A HLA-B HLA-C TNF
6 acquired immunodeficiency syndrome 30.2 HCP5 HLA-B TNF
7 graft-versus-host disease 30.2 FAS FASLG GZMB HLA-A HLA-B HLA-C
8 rubella 30.1 HLA-A HLA-B TNF
9 alopecia areata 30.0 FASLG GZMB HLA-A TNF
10 cytomegalovirus infection 30.0 FAS HLA-A HLA-B TNF
11 drug reaction with eosinophilia and systemic symptoms 30.0 HLA-B TNF
12 erythema multiforme 29.9 FASLG GZMB TNF
13 aplastic anemia 29.9 FAS FASLG HLA-A HLA-B TNF
14 skin disease 29.8 HLA-B HLA-C TGM1 TNF
15 hemophagocytic lymphohistiocytosis 29.7 FAS GNLY GZMB TNF
16 schwartz-jampel syndrome, type 1 12.3
17 sjogren syndrome 11.9
18 ritter's disease 11.8
19 5-oxoprolinase deficiency 11.4
20 auditory neuropathy spectrum disorder 11.4
21 sjogren-larsson syndrome 11.0
22 stevens-johnson syndrome/toxic epidermal necrolysis overlap syndrome 11.0
23 lupus erythematosus 10.6
24 bronchiolitis obliterans 10.5
25 bronchiolitis 10.5
26 ocular cicatricial pemphigoid 10.5
27 cutaneous lupus erythematosus 10.5
28 linear iga disease 10.5
29 cataract 10.5
30 fixed drug eruption 10.4
31 systemic lupus erythematosus 10.4
32 influenza 10.4
33 dermatitis 10.3
34 granulocytopenia 10.3
35 phenytoin or carbamazepine toxicity 10.3 HLA-A HLA-B
36 endophthalmitis 10.3
37 conjunctivitis 10.3
38 autoimmune progesterone dermatitis 10.3
39 postherpetic neuralgia 10.3 HLA-A HLA-B
40 burns 10.3
41 lymphoma 10.3
42 contact dermatitis 10.3
43 purpura 10.3
44 pemphigus 10.3
45 atrial tachyarrhythmia with short pr interval 10.3 HLA-A HLA-B
46 caplan's syndrome 10.2 FAS HLA-A
47 breast medullary carcinoma 10.2 FASLG GZMB
48 lymphocytic gastritis 10.2 FAS FASLG GZMB
49 chronic venous leg ulcers 10.2 FAS FASLG
50 breast cancer 10.2

Graphical network of the top 20 diseases related to Severe Cutaneous Adverse Reaction:



Diseases related to Severe Cutaneous Adverse Reaction
Sources

Symptoms & Phenotypes for Severe Cutaneous Adverse Reaction

About this section

Clinical features from OMIM:

608579

Human phenotypes related to Severe Cutaneous Adverse Reaction:

59 32 (show all 50)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sudden cardiac death 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001645
2 dysphagia 59 32 frequent (33%) Very frequent (99-80%),Frequent (79-30%) HP:0002015
3 nausea and vomiting 59 32 hallmark (90%) Occasional (29-5%),Very frequent (99-80%) HP:0002017
4 recurrent respiratory infections 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0002205
5 malabsorption 59 32 frequent (33%) Frequent (79-30%) HP:0002024
6 visual impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000505
7 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000083
8 photophobia 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000613
9 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
10 polydipsia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001959
11 fatigue 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0012378
12 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
13 anemia 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0001903
14 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
15 abdominal pain 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0002027
16 abnormal blistering of the skin 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0008066
17 weight loss 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0001824
18 respiratory distress 59 32 occasional (7.5%) Occasional (29-5%) HP:0002098
19 corneal erosion 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0200020
20 abnormality of the pleura 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002103
21 thrombocytopenia 59 32 occasional (7.5%) Very frequent (99-80%),Occasional (29-5%) HP:0001873
22 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
23 pancreatitis 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001733
24 abnormal myocardium morphology 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0001637
25 visual loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0000572
26 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002239
27 diarrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002014
28 erythema 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0010783
29 macule 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0012733
30 conjunctivitis 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000509
31 neutropenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001875
32 sepsis 59 32 occasional (7.5%) Very frequent (99-80%),Occasional (29-5%) HP:0100806
33 cough 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0012735
34 acute hepatic failure 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0006554
35 tracheoesophageal fistula 59 32 occasional (7.5%) Occasional (29-5%) HP:0002575
36 abnormality of neutrophils 59 32 frequent (33%) Frequent (79-30%) HP:0001874
37 abnormality of the urethra 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000795
38 dyspareunia 59 32 occasional (7.5%) Occasional (29-5%) HP:0030016
39 dysuria 59 32 occasional (7.5%) Frequent (79-30%),Occasional (29-5%) HP:0100518
40 excessive salivation 59 32 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0003781
41 restrictive ventilatory defect 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0002091
42 acantholysis 59 32 hallmark (90%) Very frequent (99-80%),Very frequent (99-80%) HP:0100792
43 entropion 59 32 occasional (7.5%) Occasional (29-5%),Occasional (29-5%) HP:0000621
44 intestinal perforation 59 32 occasional (7.5%) Occasional (29-5%) HP:0031368
45 esophageal stricture 59 32 occasional (7.5%) Occasional (29-5%) HP:0002043
46 hypokalemic metabolic alkalosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001960
47 elevated hepatic transaminases 59 Frequent (79-30%),Occasional (29-5%)
48 abnormality of the vagina 59 Occasional (29-5%)
49 elevated hepatic transaminase 32 occasional (7.5%) HP:0002910
50 abnormal vagina morphology 32 occasional (7.5%) HP:0000142

GenomeRNAi Phenotypes related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.47 HLA-A HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.47 HLA-A HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.47 HLA-A HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.47 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.47 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.47 HLA-A HLA-B HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.47 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.47 HLA-A HLA-B HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.47 HLA-A HLA-B HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.47 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.47 HLA-A HLA-B HLA-C
12 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.47 HLA-C
13 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.47 HLA-A HLA-B HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.47 HLA-A HLA-B HLA-C
15 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.47 HLA-C
16 Decreased viability GR00240-S-1 10.27 HCP5
17 Decreased viability GR00301-A 10.27 GZMB
18 Decreased viability GR00342-S-1 10.27 TLR3
19 Decreased viability GR00342-S-2 10.27 TLR3
20 Decreased viability GR00381-A-1 10.27 ENPP5 EPHX1
21 Decreased viability GR00402-S-2 10.27 CYP2C9 ENPP5 EPHX1 FAS FASLG GNLY
22 no effect GR00402-S-1 9.62 CYP2C9 ENPP5 EPHX1 FAS FASLG GNLY

MGI Mouse Phenotypes related to Severe Cutaneous Adverse Reaction:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.76 FAS FASLG HSPG2 IKZF1 NFKBIZ PTGER3
2 neoplasm MP:0002006 9.43 EPHX1 FAS FASLG IKZF1 TLR3 TNF
3 respiratory system MP:0005388 9.17 FAS FASLG HSPG2 IKZF1 NFKBIZ TLR3
Sources

Drugs & Therapeutics for Severe Cutaneous Adverse Reaction

About this section

Drugs for Severe Cutaneous Adverse Reaction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
2
Nevirapine Approved Phase 4 129618-40-2 4463
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4 Reverse Transcriptase Inhibitors Phase 4
5 Anti-HIV Agents Phase 4
6 Antiviral Agents Phase 4
7 Nucleic Acid Synthesis Inhibitors Phase 4
8 Anti-Retroviral Agents Phase 4
9 Anti-Infective Agents Phase 4
10 Cytochrome P-450 CYP3A Inducers Phase 4
11
Linagliptin Approved Phase 3 668270-12-0 10096344
12
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
13 Dulaglutide Approved, Investigational Phase 3 923950-08-7
14
Insulin Glargine Approved Phase 3 160337-95-1
15
Zinc Approved, Investigational Phase 3 7440-66-6
16
Insulin Lispro Approved Phase 3 133107-64-9
17
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
18 Hormones Phase 3,Not Applicable
19 HIV Protease Inhibitors Phase 3
20 Hypoglycemic Agents Phase 3
21 Hormone Antagonists Phase 3,Not Applicable
22 Incretins Phase 3
23 Dipeptidyl-Peptidase IV Inhibitors Phase 3
24
protease inhibitors Phase 3
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Not Applicable
26 Insulin, Globin Zinc Phase 3
27 insulin Phase 3
28 Immunoglobulins Phase 3
29 Immunoglobulin Fc Fragments Phase 3
30 Immunologic Factors Phase 3,Not Applicable
31 Antibodies Phase 3
32 Hematinics Phase 3
33
Allopurinol Approved Not Applicable 315-30-0 2094
34
Petrolatum Approved, Investigational Not Applicable 8009-03-8
35
Eslicarbazepine acetate Approved 75970-99-9, 236395-14-5 123618
36 tannic acid Approved Not Applicable
37
Prednisolone phosphate Approved, Vet_approved Not Applicable 302-25-0
38
Methylprednisolone Approved, Vet_approved Not Applicable 83-43-2 6741
39
Methylprednisolone hemisuccinate Approved Not Applicable 2921-57-5
40
Prednisolone Approved, Vet_approved Not Applicable 50-24-8 5755
41
Benzocaine Approved, Investigational Not Applicable 94-09-7, 1994-09-7 2337
42
Etanercept Approved, Investigational Not Applicable 185243-69-0
43
Prednisolone hemisuccinate Experimental Not Applicable 2920-86-7
44 Antirheumatic Agents Not Applicable
45 Free Radical Scavengers Not Applicable
46 Protective Agents Not Applicable
47 Antioxidants Not Applicable
48 Antimetabolites Not Applicable
49 Sodium Channel Blockers
50 Diuretics, Potassium Sparing

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
2 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3 linagliptine 5 mg;linagliptine 5 mg and pioglitazone 30 mg
3 A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Completed NCT01621178 Phase 3 Dulaglutide;Insulin glargine;Insulin lispro
4 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Terminated NCT00858364 Phase 3 Darbepoetin alfa;Placebo
5 Severe Cutaneous Adverse Reactions in Thailand Unknown status NCT02574988
6 HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Recruiting NCT03046914 Not Applicable
7 Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs) Recruiting NCT03176342 Not Applicable
8 An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate Recruiting NCT02520557
9 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions Completed NCT01276314 Not Applicable anti- TNF-a;Prednisolone
10 Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Recruiting NCT03659227

Search NIH Clinical Center for Severe Cutaneous Adverse Reaction

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Severe Cutaneous Adverse Reaction cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Severe Cutaneous Adverse Reaction:
Cultivated corneal epithelial stem cells for treatment of ocular surface damage
Embryonic/Adult Cultured Cells Related to Severe Cutaneous Adverse Reaction:
Limbal corneal epithelial stem cells PMIDs: 23055668

Cochrane evidence based reviews: stevens-johnson syndrome

Sources

Genetic Tests for Severe Cutaneous Adverse Reaction

About this section

Genetic tests related to Severe Cutaneous Adverse Reaction:

# Genetic test Affiliating Genes
1 Susceptibility to Severe Cutaneous Adverse Reaction 29 HLA-A HLA-B
Sources

Anatomical Context for Severe Cutaneous Adverse Reaction

About this section

MalaCards organs/tissues related to Severe Cutaneous Adverse Reaction:

41
Skin, Eye, Testes, T Cells, Liver, Lung, Salivary Gland
Sources

Publications for Severe Cutaneous Adverse Reaction

About this section

Articles related to Severe Cutaneous Adverse Reaction:

(show top 50) (show all 1065)
# Title Authors Year
1
Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome. ( 29528923 )
2018
2
Notice of Retraction and Replacement: "Autoimmune Progesterone Dermatitis Presenting as Stevens-Johnson Syndrome" (Drayer SM, Laufer LR, Farrell ME). ( 29533269 )
2018
3
Autoimmune Progesterone Dermatitis Mistaken for Stevens-Johnson Syndrome. ( 29528935 )
2018
4
Acute generalized exanthematous pustulosis simulating Stevens-Johnson syndrome/toxic epidermal necrolysis associated with the use of vismodegib. ( 29387760 )
2018
5
Severe Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome-beyond skin involvement. ( 29159901 )
2018
6
First case of Stevens-Johnson syndrome after rabies vaccination. ( 29333656 )
2018
7
Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation. ( 28689166 )
2018
8
The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population. ( 29076187 )
2018
9
Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database. ( 29387340 )
2018
10
Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience. ( 29029855 )
2018
11
Stevens-Johnson syndrome and toxic epidermal necrolysis-like cutaneous presentation of chikungunya fever: A case series. ( 29573443 )
2018
12
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn's disease: Need for a multidisciplinary approach. ( 30541717 )
2018
13
Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab. ( 29952288 )
2018
14
Anesthetic considerations in Stevens-Johnson syndrome with epilepsy for bilateral amniotic membrane grafting in eye. ( 30078868 )
2018
15
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report. ( 30301570 )
2018
16
Corneal limbal stem cell deficiency in children with Stevens-Johnson syndrome. ( 30347185 )
2018
17
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus. ( 29912772 )
2018
18
Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. ( 30282109 )
2018
19
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. ( 29176400 )
2018
20
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib. ( 29328518 )
2018
21
Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept. ( 29421925 )
2018
22
Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide. ( 29445458 )
2018
23
Selective Use of Cyclosporine for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis May Exclude Patients with Poor Prognostic Factors. ( 29559345 )
2018
24
A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 29636627 )
2018
25
Diverse expression of TNF-α and CCL27 in serum and blister of Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 29713456 )
2018
26
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. ( 29758282 )
2018
27
A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. ( 29762688 )
2018
28
Procalcitonin as a diagnostic indicator for systemic bacterial infections in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. ( 29897140 )
2018
29
Reply to: "Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need". ( 29913260 )
2018
30
Wound management strategies in Stevens-Johnson syndrome/toxic epidermal necrolysis: An unmet need. ( 29913262 )
2018
31
Stevens-Johnson syndrome/toxic epidermal necrolysis in Jewish and Arab populations. ( 29972250 )
2018
32
Carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a Filipino with positive HLA-B75 serotype. ( 30018035 )
2018
33
ISMP Adverse Drug Reactions: Propofol-Related Infusion Syndrome (PRIS)1,2; Ivermectin-Induced Stevens-Johnson Syndrome; Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis From Fexofenadine; Memantine-Related Drug Eruption. ( 30038437 )
2018
34
Tolerance Induction to Antituberculosis Drugs in a Patient With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Overlap. ( 30083412 )
2018
35
Defining Regional Differences in Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Tool to Improve Drug Safety? ( 30120778 )
2018
36
Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. ( 30242287 )
2018
37
Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. ( 30298362 )
2018
38
Novel complication of Flakka: Stevens-Johnson syndrome/Toxic epidermal necrolysis overlap. ( 30503281 )
2018
39
A diagnosis of Stevens-Johnson Syndrome (SJS) in a patient presenting with superficial keratitis. ( 30128368 )
2018
40
Influenza B virus infection and Stevens-Johnson syndrome. ( 29282756 )
2018
41
Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. ( 29315761 )
2018
42
Survey of Nonprescription Medication and Antibiotic Use in Patients with Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Overlap Syndrome. ( 29389866 )
2018
43
Chronic Ocular Sequelae of Stevens-Johnson Syndrome in Children: Long-term Impact of Appropriate Therapy on Natural History of Disease. ( 29421293 )
2018
44
Ethosuximide-induced Stevens-Johnson syndrome: Beneficial effect of early intervention with high-dose corticosteroid therapy. ( 29430697 )
2018
45
ISMP Adverse Drug Reactions: Influenza Vaccine-Induced Stevens-Johnson Syndrome; Vilazodone-Induced Nightmares; Dabigatran-Induced Pustular Eruptions; Neurotoxic and Cardiotoxic Symptoms After Cannabis Concentrate Exposure; Rosuvastatin-Induced Skin Eruption. ( 29434381 )
2018
46
The use of cyclosporine for Stevens-Johnson syndrome-toxic epidermal necrolysis spectrum at the University of Louisville: A case series and literature review. ( 29469760 )
2018
47
The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. ( 29569740 )
2018
48
Vancomycin-Induced Stevens-Johnson Syndrome in a Boy Under 2 Years Old: An Early Diagnosis by Granulysin Rapid Test. ( 29594082 )
2018
49
Wound care for Stevens-Johnson syndrome and toxic epidermal necrolysis. ( 29601936 )
2018
50
The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. ( 29607330 )
2018
Sources

Variations for Severe Cutaneous Adverse Reaction

About this section

ClinVar genetic disease variations for Severe Cutaneous Adverse Reaction:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HLA-B HLA-B*15: 02 undetermined variant risk factor
2 HLA-B HLA-B, HLA-B*5801 undetermined variant risk factor
3 HLA-A NM_001242758.1(HLA-A): c.776delC (p.Pro259Leufs) deletion not provided GRCh38 Chromosome 6, 29944278: 29944278
Sources

Expression for Severe Cutaneous Adverse Reaction

About this section
Search GEO for disease gene expression data for Severe Cutaneous Adverse Reaction.
Sources

Pathways for Severe Cutaneous Adverse Reaction

About this section

Pathways related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.82 FAS FASLG HLA-A HLA-B HLA-C TLR3
2
Allograft rejection 1 37
Show member pathways
 12.6 FAS FASLG GNLY GZMB HLA-A HLA-B
3
Influenza A 37
Show member pathways
 12.55 FAS FASLG HLA-A HLA-B HLA-C TLR3
4
Human cytomegalovirus infection 37
Show member pathways
 12.49 FAS FASLG HLA-A HLA-B HLA-C HSPG2
5
DREAM Repression and Dynorphin Expression 64
Show member pathways
 12.35 FAS FASLG GZMB TNF
6
Human T-cell leukemia virus 1 infection 37
12.29 HLA-A HLA-B HLA-C TNF
7
NF-kappaB Signaling 4
12.21 FAS FASLG GZMB IKZF1 NFKBIZ TLR3
8
Proteoglycans in cancer 37
12.15 FAS FASLG HSPG2 TNF
9
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.13 FAS FASLG GZMB TNF
10
Epstein-Barr virus infection 37
12.11 FAS HLA-A HLA-B HLA-C TNF
11
Apoptosis and Autophagy 4
12.1 FAS FASLG GZMB TNF
12
Necroptosis 37
Show member pathways
 12.06 FAS FASLG TLR3 TNF
13
IL12-mediated signaling events 1
Show member pathways
 11.83 FASLG GZMB HLA-A
14
Innate Lymphoid Cell Differentiation Pathways 65
11.66 GZMB IKZF1 TNF
15
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 11.64 FAS FASLG GZMB HLA-A HLA-B HLA-C
16
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.61 FASLG IKZF1 TNF
17
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.45 FASLG GZMB HLA-A TNF
18
Photodynamic therapy-induced AP-1 survival signaling. 1
11.39 FAS FASLG TNF
19
Signal transduction_JNK pathway 22
11.31 FAS FASLG TNF
20
African trypanosomiasis 37
11.2 FAS FASLG TNF
21
Antigen Presentation- Folding, assembly and peptide loading of class I MHC 66
11.03 HLA-A HLA-B HLA-C
Sources

GO Terms for Severe Cutaneous Adverse Reaction

About this section

Cellular components related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 recycling endosome membrane GO:0055038 9.54 HLA-A HLA-B HLA-C
2 phagocytic vesicle membrane GO:0030670 9.5 HLA-A HLA-B HLA-C
3 cell surface GO:0009986 9.5 FAS FASLG HLA-A HLA-B HLA-C TLR3
4 ER to Golgi transport vesicle membrane GO:0012507 9.43 HLA-A HLA-B HLA-C
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-A HLA-B HLA-C
6 MHC class I protein complex GO:0042612 8.8 HLA-A HLA-B HLA-C
7 extracellular exosome GO:0070062 10.01 FAS FASLG HLA-A HLA-B HLA-C HSPG2

Biological processes related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.93 FAS FASLG HLA-A HLA-B HLA-C TNF
2 inflammatory response GO:0006954 9.92 HSPG2 NFKBIZ PTGER3 TLR3 TNF
3 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.75 FAS FASLG TNF
4 positive regulation of inflammatory response GO:0050729 9.74 NFKBIZ TLR3 TNF
5 interferon-gamma-mediated signaling pathway GO:0060333 9.73 HLA-A HLA-B HLA-C
6 type I interferon signaling pathway GO:0060337 9.72 HLA-A HLA-B HLA-C
7 antigen processing and presentation GO:0019882 9.65 HLA-A HLA-B HLA-C
8 apoptotic signaling pathway GO:0097190 9.62 FAS FASLG TLR3 TNF
9 positive regulation of chemokine production GO:0032722 9.61 TLR3 TNF
10 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.61 HLA-A HLA-B HLA-C
11 microglial cell activation GO:0001774 9.6 TLR3 TNF
12 necroptotic process GO:0070266 9.59 FASLG TLR3
13 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.58 FAS FASLG
14 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.58 HLA-A HLA-B HLA-C
15 positive regulation of chemokine biosynthetic process GO:0045080 9.54 TLR3 TNF
16 positive regulation of T cell mediated cytotoxicity GO:0001916 9.54 HLA-A HLA-B HLA-C
17 positive regulation of fever generation GO:0031622 9.51 PTGER3 TNF
18 protection from natural killer cell mediated cytotoxicity GO:0042270 9.49 HLA-A HLA-B
19 extrinsic apoptotic signaling pathway GO:0097191 9.46 FAS FASLG TLR3 TNF
20 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.43 HLA-A HLA-B HLA-C
21 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.13 HLA-A HLA-B HLA-C
22 necroptotic signaling pathway GO:0097527 8.92 FAS FASLG TLR3 TNF

Molecular functions related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.8 HLA-A HLA-B HLA-C
Sources

Sources for Severe Cutaneous Adverse Reaction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....